中国肿瘤生物治疗杂志2018，Vol.25Issue(1)：28-34,7.DOI:10.3872/j.issn.1007-385x.2018.01.005
转移性肾细胞癌生物治疗的现状及展望
Current situation and prospect of biotherapy of metastatic renal cell carcinoma
摘要
Abstract
Due to the inherent resistance,renal cell carcinoma (RCC) is insensitive to radiotherapy and chemotherapy;thus,biotherapy is the only option for patients with metastatic renal cell carcinoma (mRCC).With the further understanding of RCC,small molecule targeted drug therapy has gradually replaced the previous cytokine therapy.In recent years,new immunotherapy has become the focus of research in the biotherapy of RCC.Small molecule targeted drug therapy and new immunotherapy have shown great advantages in the treatment,they can improve the survival time and quality of life for RCC patients;however,the low response rate,drug-resistance,side effects and other issues also appear.Thus,providing personalized treatment to bring greater benefits for RCC patients is the goal for clinical practitioners.关键词
肾细胞癌/生物治疗/靶向治疗/免疫疗法/精准治疗Key words
renal cell carcinoma/biotherapy/targeted therapy/immunotherapy/accurate treatment分类
医药卫生引用本文复制引用
甘欣欣,王林辉..转移性肾细胞癌生物治疗的现状及展望[J].中国肿瘤生物治疗杂志,2018,25(1):28-34,7.基金项目
国家自然科学基金重点项目(No.281730073) （No.281730073）
第二军医大学精准医学转化应用研究专项(No.2017JZ22).Project supported by the National Natural Science Foundation of China (No.281730073),and the Translation and Application of Precise Medicine of Second Military Medical Unversity(No.2017JZ22) （No.2017JZ22）
